丨2026年8月14日星期五丨 NO.1 艾力斯医药获得ArriVent潜在全球首创ADC权益 8月13日,艾力斯宣布与ArriVent BioPharma, Inc. (ArriVent)签署战略合作协议,公司获得在中国研究、开发、生产、注册以及商业化抗体偶联药物(ADC)AST12608/ARR-002的独占许可。 点评:AST12608/ARR-002的引进,是艾力斯从肺癌向多肿瘤领域...
Source Link丨2026年8月14日星期五丨 NO.1 艾力斯医药获得ArriVent潜在全球首创ADC权益 8月13日,艾力斯宣布与ArriVent BioPharma, Inc. (ArriVent)签署战略合作协议,公司获得在中国研究、开发、生产、注册以及商业化抗体偶联药物(ADC)AST12608/ARR-002的独占许可。 点评:AST12608/ARR-002的引进,是艾力斯从肺癌向多肿瘤领域...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.